Form 4: Tempus AI CEO Eric Lefkofsky Reports Significant Share Transactions

Eric Lefkofsky, CEO and Chairman of Tempus AI, reports multiple transactions involving Class A Common Stock, including distributions and sales, as detailed in a Form 4 filing.

Summary

• Eric Lefkofsky, CEO and Chairman of Tempus AI, filed a Form 4 detailing changes in beneficial ownership of the company's Class A Common Stock on February 27, 2025.
• The transactions include pro rata distributions without additional consideration from Innovation Group Investors, L.P. 2011 Series and Lightbank Investments 1B, LLC.
• Lefkofsky also reported sales of Class A Common Stock at a price of $58.75 per share.
• These sales were executed by Innovation Group Investors, L.P. 2011 Series (1,580,928 shares), Lightbank Investments 1B, LLC (115,751 shares), Innovation Group Investors, L.P. Series 1B (145,966 shares), and Lightbank Global LLC (1,397,589 shares).
• Following these transactions, Lefkofsky directly owns 4,895,589 shares of Class A Common Stock.
• He also has indirect ownership through various entities including Innovation Group Investors, L.P. 2011 Series, Lightbank Investments 1B, LLC, Blue Media, LLC, 346 Long LLC, Gray Media, LLC, Black Media, LLC, and Lefkofsky Family Foundation.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions without expressing a clear positive or negative outlook. The sales could be viewed with slight negativity, but the distributions are neutral.

Negatives

• The Form 4 filing indicates sales of shares by entities associated with Eric Lefkofsky, which could be interpreted negatively by some investors.

Risks

• Sales of shares by insiders or related entities can sometimes create uncertainty among investors regarding the company's future prospects.

Industry Context

Form 4 filings are a standard part of regulatory compliance for company insiders and provide transparency into their transactions in the company's stock. Investors often monitor these filings for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for all publicly traded companies in the US.
• The information provided in this filing is consistent with the level of detail expected in such reports.
• Comparable companies such as Foundation Medicine (acquired by Roche) and Guardant Health also have similar insider transaction reporting requirements.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The transactions could affect investor confidence depending on their interpretation of the insider activity.

Key Dates